关注“银龄”需求 GSK中国围绕多发性骨髓瘤诊疗达成多项合作

Core Insights - GSK has launched an innovative initiative focused on multiple myeloma (MM) patients during the 8th China International Import Expo, aiming to enhance patient support through collaboration with the medical community and NGOs [1] - A strategic cooperation memorandum has been signed between GSK and the Beijing Zhongkanglian Public Welfare Foundation to establish an MM working group, improving management levels and reducing the burden on doctors [1] - The injection of mabeparvovec, an ADC drug, is recognized as a first-line treatment for relapsed/refractory MM according to the CSCO guidelines, highlighting the importance of early intervention during the first relapse phase [1] Group 1 - GSK's ADC therapy, mabeparvovec, has been included in the breakthrough therapy category by the National Medical Products Administration of China, with its application for market approval under priority review [2] - The company plans to accelerate research and development in the specialty drug sector [2]